Genmab A/S (GMAB) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Genmab A/S (GMAB) has outperformed Grifols S.A. (GRFS) over the past year, gaining 12.3% versus a loss of 21.8%. Over five years, GMAB leads with a -17.5% price change compared with -47.3% for GRFS. Genmab A/S is the larger company by market cap ($22.54 billion vs $5.10 billion), about 4.4 times the size.
On valuation, Grifols S.A. trades at a lower forward P/E (5.2x vs 24.0x for Genmab A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | GRFS |
|---|---|---|
| Share price | $36.65 | $7.50 |
| Market cap | $22.54B | $5.10B |
| 1-day change | -3.04% | -0.27% |
| YTD return | +18.99% | -19.79% |
| 1-year return | +12.29% | -21.79% |
| 5-year return | -17.51% | -47.26% |
| P/E ratio (TTM) | 28.86 | 9.74 |
| Forward P/E | 24.03 | 5.20 |
| EPS (TTM) | $1.27 | $0.77 |
| Dividend yield | 0.00% | 1.41% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | — |
| Revenue growth (YoY) | +19.19% | — |
| Net income (latest FY) | $963.00M | — |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | — |
| Net margin | 25.89% | — |
| 52-week high | $40.17 | $9.90 |
| 52-week low | $23.62 | $6.96 |
| Distance from 52-week high | -8.76% | -24.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +17.93% | +44.93% |
| Average volume | 2.80M | 580.72K |
| Shares outstanding | 614.90M | 258.22M |
| Employees | 3,119 | 25,258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.4 times larger than Grifols S.A. by market value ($22.54B vs $5.10B).
- GMAB has outperformed GRFS by 34.1 percentage points over the past year.
- Genmab A/S trades at a higher earnings multiple (28.9x vs 9.7x trailing P/E).
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
GMAB vs GRFS FAQ
Which is bigger, Genmab A/S or Grifols S.A.?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.54B compared with $5.10B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, GMAB or GRFS?
GMAB returned +12.29% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or GRFS?
GRFS has the lower trailing P/E at 9.7, versus 28.9 for GMAB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Genmab A/S or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.41%, while Genmab A/S does not currently pay a regular dividend.
Are Genmab A/S and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.